Williams J G, Croft D N
Scand J Gastroenterol Suppl. 1980;65:29-33.
Technetium-99m pertechnetate is known to concentrate in the stomach following intravenous injection, but there is controversy on the cellular site of this uptake, with evidence for both the mucous and parietal cells being primarily responsible. Gastric uptake following intravenous pertechnetate has been studied in patients with non-ulcer dyspepsia and peptic ulcer, using a gamma camera and computer processing with regions of interest. Under identical conditions in any one patient, quantification of uptake at 20 min is reproducible to an accuracy of +/- 6%. Six patients with gastric ulcer were studied before and 3 weeks after starting treatment with carbenoxolone. There was a rise in uptake in 5 subjects with a mean percentage increase of 25%. The effect of cimetidine was studied in six patients with either gastric or duodenal ulcer. There was little change in uptake (mean 6%). These preliminary data would support the hypothesis that concentration of pertechnetate occurs primarily in the mucous cell.
已知静脉注射后，高锝[99mTc]酸盐会在胃中聚集，但对于这种摄取的细胞部位存在争议，有证据表明黏液细胞和壁细胞都可能起主要作用。使用γ相机和感兴趣区域的计算机处理技术，对非溃疡性消化不良和消化性溃疡患者静脉注射高锝[99mTc]酸盐后的胃摄取情况进行了研究。在任何一名患者的相同条件下，20分钟时摄取量的定量可重复性达到±6%的准确度。对6例胃溃疡患者在开始使用甘珀酸治疗前及治疗3周后进行了研究。5名受试者的摄取量增加，平均增加百分比为25%。对6例胃溃疡或十二指肠溃疡患者研究了西咪替丁的作用。摄取量几乎没有变化（平均6%）。这些初步数据支持高锝[99mTc]酸盐主要在黏液细胞中聚集的假说。
